The digestive system cancers are leading cause of cancer-related death worldwide, and have high risks of morbidity and mortality. More and more long non-coding RNAs (lncRNAs) have been studied to be abnormally expressed in cancers and play a key role in the process of digestive system tumour progression. Plasmacytoma variant translocation 1 (PVT1) seems fairly novel. Since 1984, PVT1 was identified to be an activator of MYC in mice. Its role in human tumour initiation and progression has long been a subject of interest. The expression of PVT1 is elevated in digestive system cancers and correlates with poor prognosis. In this review, we illustrate the various functions of PVT1 during the different stages in the complex process of digestive system tumours (including oesophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma and pancreatic cancer). The growing evidence shows the involvement of PVT1 in both proliferation and differentiation process in addition to its involvement in epithelial to mesenchymal transition (EMT). These findings lead us to conclude that PVT1 promotes proliferation, survival, invasion, metastasis and drug resistance in digestive system cancer cells. We will also discuss PVT1's potential in diagnosis and treatment target of digestive system cancer. There was a great probability PVT1 could be a novel biomarker in screening tumours, prognosis biomarkers and future targeted therapy to improve the survival rate in cancer patients.
| INTRODUCTION
Cancer of the digestive system is the leading cause of cancer-related death worldwide. Among all the types of cancers, the incidence of gastric cancer (GC), hepatocellular cancer (HCC) and colorectal cancer (CRC) is high with a high mortality rate. 1, 2 The prognosis of patient with digestive system cancers depends mostly upon the stage of the cancer at the time of diagnosis. However, current therapeutic methods for advanced stage cancers still have some limitations and it is hard to detect the cancers at their early stages due to the lack of efficient biomarkers. Therefore, identification of these potential efficient biomarkers may help in the early stage diagnosis of such cancers.
Recently, long non-coding RNAs (lncRNAs), a subclass of noncoding RNAs with >200 nucleotides, has been studied to be abnormally expressed in digestive system cancers and has a key role in the course of tumour development. Recently, several studies have focused on analysing their mechanisms and networks to expose their role in development of cancer. Among lncRNAs, Plasmacytoma variant translocation 1 (PVT1) seems fairly important. PVT1 belongs to lncRNA class, and is encoded by the PVT1 gene (also known as the Pvt1 oncogene). In 1984, PVT1 was identified as an activator of MYC in plasmacytoma variant translocations in mice. 3 In humans, PVT1 is located on chromosomal 8q24.21, as a large locus (>30 kb) from 128806779 to 129113499, about 57 kb distant from and downstream of the c-Myc gene.
4,5
Amplification of 8q24 encoded c-Myc and PVT1 are often found in varieties of human malignancies. Coamplication of human PVT1
and c-Myc has been found to be associated with rapid progression of breast cancer as well as poor clinical survival in breast cancer. 6 
PVT1
and c-Myc may serve as transcription activator to each other. 7 Six annotated miRNAs produced by PVT1 have been discovered, including miR-1204, miR-1205, miR-1206, miR-1207-3p, miR-1207-5p and miR-1208. 8 But the relationships between PVT1 and other factors remain largely unknown.
The dysregulation of PVT1 was found in varieties of human diseases. PVT1 was reported to mediate the development of diabetic nephropathy through extracellular matrix (ECM) accumulation. 9 The expression of PVT1 was low in normal tissue but its expression was found to be highly increased in transformed cell lines. 11, 20 It was also associated with poor prognosis in cervical cancer patients. 13 Overexpression of PVT1 has contributed to the pathophysiology of ovarian and breast cancer, 12 and cause cisplatin resistance by regulating apoptotic relevant pathways. 21 To sum, various studies have revealed that PVT1 plays significant roles in tumourogenesis, making it a potential cancer biomarker.
Plasmacytoma variant translocation 1 was found to be upregulated in human tumours, especially in digestive system cancers.
However, its clinical significance in digestive system tumours remains obscured. In this review, we will discuss the biological functions of PVT1 in digestive system cancers ( Table 1 ). PVT1 will be a potentially useful tool for the diagnosis and treatment targeting of digestive system tumours.
| OESOPHAGEAL CANCER
Oesophageal cancer is the sixth most common cause of cancer death among males and the ninth most common cause of cancer death among females worldwide. 2 In 2010, the data of China showed that the morbidity and mortality of oesophageal cancer were 21.88/100000 and 15.85/100000, respectively. 7 Even though, pathogenesis of oesophageal cancer is still unclear, several factors appear as consistent reasons such as tobacco, alcohol, reflux oesophagitis, dietary habits, nutrition, along with environmental factors. 22 Currently, there are no ideal biomarkers, which can be used in screening oesophageal cancer strategies. 23 LncRNA nuclear paraspeckle assembly transcript 1 (NEAT1), LncRNA ANRIL, HOX transcript anti-sense intergenic RNA (HOTAIR) and SOX2 overlapping transcript (SOX2OT) were found to be associated with oesophageal cancer.
24-27
Epithelial-mesenchymal transition (EMT) is a biological process in which epithelial cells lost cell polarity, adhesion properties, but obtain migratory and invasive abilities become multipotent mesenchymal stem cells. Decreased E-cadherin and increased N-cadherin are the hallmarks for the EMT. EMT is a vital step in cancer progression, invasion and metastasis.
In the last 2 years, role of PVT1 in development and progression of oesophageal cancer has attracted the attention of several scholars.
PVT1 was associated with tumour stage, metastasis, as well as regulating the cell invasion in vitro by inducing EMT. 
| GASTRIC CANCER
Being a disease of high mortality, GC is the second commonest cause of cancer-related death worldwide. 2 In 2011, more than 400 000 patients were diagnosed with GC in China, among which there were estimated 300 000 deaths in China. 30 The epidemiology study illustrated that environmental factors and lifestyles are key contributors to the aetiology of GC. 31 Though, the treatment option for GC patients is still challenging, surgery and systemic chemotherapy are the mainstay treatments. 32 Nevertheless, the exact molecular mechanism of GC is still obscured. Several genetic alterations are involved in the predisposition to GC, such as oncogenes, tumour suppressor genes and growth factors. 33 Hence, it is urgent to find specific biomarkers in the diagnosis of GC and investigate therapeutic targets for GC. Clinically, the overexpression of PVT1 was specifically associated with deeper invasion depth, as well as advanced TNM stages. PVT1
plays an important role in G1 arrest. 36 Another study revealed that PVT1 might act as a "sponge" to hinder miR-152 in GC cells. Multidrug Resistance (MDR) is one of the major reasons for therapy failure in GC, which leads to recurrence and metastasis of GC.
PVT1 was overexpressed both in tissues and cells in cisplatin-resistant patients. Overexpression of PVT1 has anti-apoptotic activity, and improves the expression of MDR-related genes such as MDR1, mTOR, MRP as well as HIF-1α in cisplatin-resistant GC cells. PVT1 might stimulate the development of MDR via regulation of mTOR/HIF-1α/P-gp along with MRP1 signalling pathway in MDR-gastric cancer. 35 The underlying mechanism of PVT1 in apoptosis induction is still not clear, so
further study is needed.
In conclusion, PVT1 has been found to be linked with tumour suppressor or oncogenic pathways of GC, 37 and altered expression of PVT1 was associated with the occurrence and development of GC ( Figure 1 ). This finding provides evidence that PVT1 may be considered as a candidate detection biomarker as well as a novel therapeutic target in GC.
| COLORECTAL CANCER (CRC)
Colorectal cancer is the third most common malignancy and has the third highest mortality rate in the United States. 50 Although, the death rate has declined for several decades due to the adoption of screening strategies and the improvement of standard treatment, 51 
| HEPATOCELLULAR CARCINOMA
Hepatocellular cancer is the most common primary cancer of the liver.
Even though several diagnostic and treatment techniques are available for HCC, it has a very poor prognosis.
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Patched1 (PTCH1) negatively regulates the Hedgehog (Hh) pathway. MicroRNA-152 (miR-152) prevents liver fibrosis from decreasing PTCH1 methylation. 56 PVT1 down-regulates PTCH1 expression through competitively binding miR-152, contributing to EMT process in liver fibrosis. 57 In addition, PVT1 and uc002mbe.2 in sera provides a novel supplementary method for the diagnosis of HCC, which were related to tumour size, serum bilirubin and Barcelona Clinic Liver Cancer (BCLC) stages. 58 Further analysis showed that the expression level of PVT1 was significantly elevated in HCC tissues and patients with upregulated PVT1 had a poor clinical prognosis. The pro-tumourigenic effect of PVT1 on cell proliferation, cell cycling and stem cell-like properties of HCC cells were detected by stabilizing the NOP2 protein both in vitro and in vivo. The lncRNA-PVT1/NOP2 pathway may play an important role in the treatment of HCC.
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As a conclusion, PVT1
may act as an oncogene in HCC, suggesting its beneficial effects as a prognostic marker and a therapeutic target.
| PANCREATIC CANCER (PC)
Pancreatic cancer is the seventh most common cause of cancer death worldwide. 2 However, it has the poorest survival rate among all types of cancers. Till now, the overall 5-year survival rate of PC patients is less than 5%, without apparent improvement over the past two decades. 60 Currently, there is only one biomarker, carbohydrate antigen 19-9 (CA19-9), which is approved by U.S. Food and Drug Administration (FDA). 61 However, significant limitations of CA19-9 also exist, including poor sensitivity, increased false positivity in obstructive jaundice patients (10%-60%) and false negative results in Lewis negative phenotypes (5%-10%). 62 Additionally, normal CA19-9 level is also found in patients with localized diseases, and overexpressed CA19-9 levels may also exist in some bile duct diseases such as cholangitis, calculus of bile duct, non-malignant jaundice, along with cholangiocarcinoma. [63] [64] [65] Therefore, it is urgent to find specific and sensitive biomarker for PC to improve clinical outcomes.
Till now, several lncRNAs, such as H19, HOTAIR, along with MALAT1 sensitivity and specificity. This result implies that salivary HOTAIR and PVT1 could be a novel non-invasive and specific biomarker for the detection of PC. However, these findings still need large-scale validation.
To investigate the relationship between PVT1 and prognosis of PC, Huang et al 68 found that increased expression of the PVT1 is correlated with tumour progression and multivariate cox regression analyses. This study revealed that PVT1 could be an independent prognostic factor for poor overall survival rate in PC patients.
| CONCLUSIONS AND FUTURE PERSPECTIVES
Plasmacytoma variant translocation 1 is a comparatively wellcharacterized oncogenic lncRNA, which is up-regulated in cancers, especially in many digestive system cancers, which includes oesophageal cancer, GC, HCC, CRC and PC. We reviewed PVT1 interaction with DNA, RNA, as well as related proteins in occurrence of digestive system cancers. It is tempting to speculate that PVT1 may interrupt definitive steps in numerous digestive system cancer suppressive and oncogenic pathways. PVT1 could promote tumour cell proliferation, migration and invasion. PVT1 up-regulation is usually associated with poor prognosis. PVT1 will be a potentially useful biomarker for diagnosis and therapeutic targets of digestive system tumours. However, there is still lack of the independent cohort study for validation. Thus, multicentre studies will be needed, which can enhance the clinical utility of PVT1 as an effective biomarker.
